there is still alot of ugly in this 4C and also always weary of...

there is still alot of ugly in this 4C and also always weary of what is not reported. what struck me a very real poor deal was SB having exclusivity extended indefintely due to delays in forming the partnership with them,IMO this is not good news for SH. other areas have for this management are listed below:

- staff costs nearly 5.5 mill for quarter.  - management please listen to SH take a haircut now!

- R&D down on year,as point above some management haircuts could divert more funds into this critical area -

- very low single digit for infusion business their core business

- no mention of sizable hospital contracts in US - believe WP said 2-3 were imminent in his previous 4C

- no clarity on recapitalisation plan since the VS -now over 3 months ago -  what is the real issue?

- slowing of growth in US on previous years - check the data!

- no clarity on revenue numbers in some regions e.g Europe/Emerging  % is a poor metric to us if growing from low baseline or site activation  what does that mean in numbers!

- continual delay in TGA approval and stoppage of SAS programme. This is been on market for 5 years in US & Europe. something not right there

- underestimating hurdles in emerging markets like India  andd spending to reach other small markets

-low cash balance $6.5m, most of which will be taken up by salaries

-if company do not get additional capitall this will put it in a precarious position by end of year. someone then may pick up the pieces very cheap

there are plenty of other things very dissatisfied here and we still have no timetable when the company will start trading on ASX. whole thing is mess and these folks still taking their big packets. what a joke. hopefully will get a 2nd strike at next AGM and new board members will make the right decisions for future.